Speaking of Urology: 2023 AUA Highlights
Adam B. Weiner, MD, and Ruchika Talwar, MD, discuss some of the notable urologic oncology abstracts that were presented at the 2023 AUA meeting.
In this episode of Speaking of Urology®, Adam B. Weiner, MD, and Ruchika Talwar, MD, discuss some of the notable urologic oncology abstracts that were presented at the 2023 American Urological Association Annual meeting, which was held April 28-May 1 in Chicago, Illinois. Weiner is a urologic oncology fellow at the University of California, Los Angeles, and Talwar is a urologic oncology fellow at Vanderbilt University in Nashville, Tennessee.
This recap was originally presented by Dr. Weiner and Dr. Talwar during a live Twitter Spaces event held by Urology Times. In the discussion, Weiner and Talwar touch on the followed abstracts:
- LBA02-09: EMBARK: A phase 3 randomized study of enzalutamide or placebo plus leuprolide acetate and enzalutamide monotherapy in high-risk biochemically recurrent prostate cancer
- LBA02-11: Updated progression-free survival from PRESTO: a phase 3 randomized study of androgen annihilation for high-risk biochemically relapsed prostate cancer (AFT-19)
- LBA02-03 First results from SunRISE-1 in patients with BCG unresponsive high-risk non–muscle-invasive bladder cancer receiving TAR-200 in combination with cetrelimab, tar-200, or cetrelimab alone
- LBA02-08 Results from the extended follow-up in patients with muscle-invasive bladder cancer in the CHeckMATE 274 trial
- LBA03-01: 89Zr-DFO-girentuximab for PET/CT Imaging of Indeterminate Renal Masses - Results from Phase 3 ZIRCON Study
Don’t forget to subscribe to Speaking of Urology® on Spotify, Apple Podcasts, or anywhere that podcasts are available.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.
